Ivabradine in Cirrhotic Cardiomyopathy

Launched by POST GRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH, CHANDIGARH · Sep 28, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Ivabradine, alongside another heart medication, Carvedilol, in patients with a condition known as cirrhotic cardiomyopathy. This condition occurs in people with liver cirrhosis and can lead to problems with heart function. The trial aims to see if adding Ivabradine to Carvedilol can help improve heart health by lowering the heart rate in patients who have been diagnosed with left ventricular diastolic dysfunction, which is a specific type of heart problem.

To participate in this trial, individuals must be between 18 and 65 years old, have liver cirrhosis confirmed by medical tests, and show signs of the heart dysfunction mentioned earlier. Over the course of the study, participants will be randomly assigned to receive either the combination of both medications or just Carvedilol alone. They will be monitored for changes in heart and kidney function, as well as overall health, at the beginning of the study and then again at 6 and 12 months. This trial is currently recruiting, and it's important to note that certain health conditions, like chronic kidney disease or heart rhythm disorders, may prevent someone from being eligible to join.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age range of 18-65 years
• • Cirrhosis, as diagnosed by histology or clinical, laboratory and USG findings,
• • LV diastolic dysfunction on 2D echocardiography
• Exclusion Criteria:
• • Chronic renal disease
• • Patient already on beta blocker
• • Pregnancy and peripartum cardiomyopathy
• • Hypertension
• • Coronary artery disease
• • Valvular heart disease
• • Sick sinus syndrome/ Pacemaker
• • Cardiac rhythm disorder
• • Hypothyroidism
• • Hyperthyroidism
• • Portal vein thrombosis
• • Transjugular intrahepatic porto systemic shunt (TIPS) insertion
• • Hepatocellular carcinoma
• • Anemia Hb \< 8gm/dl in females, and \< 9 gm/dl in males